Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations
ABCP therapy for <i>EGFR</i>-positive non-squamous NSCLC is a promising option, similar to immune checkpoint inhibitor-free platinum-based combination therapy. Therefore, prospective trials are necessary to confirm the efficacy of these treatments.
Authors
- Sadakatsu Ikeda (ORCID: https://orcid.org/0000-0003-1629-7171)
- Kei Nakashima (ORCID: https://orcid.org/0000-0001-6080-1801)
- Ayumu Otsuki (ORCID: https://orcid.org/0000-0001-9093-3442)
- Hironori Kobayashi (ORCID: https://orcid.org/0000-0001-9091-3521)
- Yu Oyama (ORCID: https://orcid.org/0000-0001-6440-8310)
Institutions
- Kameda Medical Center (JP)
Publication Details
- Journal
- Cureus
- Published
- 2024-08-20
- DOI
- https://doi.org/10.7759/cureus.67307
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42